WeForNews | Latest News, Breaking News, News Updates Drinking coffee may reduce heart disease risk | WeForNews | Latest News, Blogs
Connect with us

Health

Drinking coffee may reduce heart disease risk

Published

on

Coffee

London, Nov 27 : Coffee consumption is associated with reduced risk of metabolic syndrome (Mets), say researchers adding that MetS increases the risk of cardiovascular problems, including coronary heart disease and stroke.

According the study, Assistant Professor Giuseppe Grosso from the University of Catania, Italy, reviewed his own scientific research on the association between coffee consumption and MetS in Polish and Italian cohorts and explored the potential mechanistic perspectives behind the inverse association.

His research suggests that polyphenols contained in coffee may be involved in the inverse association, specifically phenolic acids and flavonoids.

He also reviewed research that suggests that moderate coffee consumption is associated with a reduction of CVD, cancer, all-cause mortality and type 2 diabetes.

For the findings, Associate Professor Estefania from Toledo University of Navarra, Spain, reviewed meta-analyses considering associations between coffee consumption and MetS and discussed work in a Mediterranean cohort.

Her research involved 22,000 people and specifically considered caffeinated and decaffeinated coffee.

The study concluded that moderate coffee consumption (one to four cups per day) was associated with reduced risk of MetS, whilst higher intakes were not.

This was reported for both regular and decaffeinated coffee.

The inverse association between coffee consumption and metabolic syndrome was shown in both men and women, said the study.

Meta-analyses also found that a moderate consumption of both caffeinated and decaffeinated coffee may be associated with a reduced risk of metabolic syndrome.

The study was presented at the 13th European Nutrition Conference organised by the Federation of European Nutrition Societies (FENS) in Dublin, Ireland.

Cities

Delhi reports 51 cases of minor adverse events post vaccination

As many as 1,91,181 people were vaccinated on day one of India’s first phase of the coronavirus vaccination drive.

Published

on

By

Covid 19 Vaccine

Hours after the Health Ministry announced on January 16 that India has reported no case of post-vaccination hospitalisation yet, 51 persons complained of minor adverse events in Delhi. Another person developed severe adverse event following immunization and had to be referred to the AEFI centre.

Out of a total of 4,319 healthcare and frontline workers who were vaccinated on Jnauary 16 in the National Capital, two healthcare workers at NDMC’s Charak Palika Hospital reported mild adverse event post-vaccination including mild tightness in the chest. They were kept under observation by AEFI team and discharged 30 minutes later after they felt at ease. The two other cases were reported from Northern Railway Central Hospital, of which one was referred to the AEFI centre, the Delhi government has informed.

As many as 1,91,181 people were vaccinated on day one of India’s first phase of the coronavirus vaccination drive.

Beneficiaries from 11 states and union territories across India received Covishield or Covaxin shots on the first day of the vaccination drive, namely, Assam, Bihar, Delhi, Haryana, Karnataka, Maharashtra, Odisha, Rajasthan, Tamil Nadu, Telangana, and Uttar Pradesh.

Follow our coverage of the coronavirus crisis here

Continue Reading

Health

Bharat Biotech to pay compensation if Covaxin causes side-effects

The vaccine maker said in phase 1 and phase 2 clinical trials, Covaxin has demonstrated the ability to produce antidotes against COVID- 19

Published

on

By

COVAXIN Corona Covid vaccine

Hyderabad, January 16: Bharat Biotech, which has received a government purchase order for supply of 55 lakh doses of Covaxin, a COVID-19 vaccine, said the company would pay compensation to recipients in case of any serious adverse effects experienced after receiving the antidote.

In the consent form to be signed by the vaccine recipients, Bharat Biotech said: “In case of any adverse events or serious adverse events, you will be provided medically recognised standard of care in the government designated and authorised centres/hospitals.”

“The compensation for serious adverse event will be paid by sponsor (BBIL) in case if the SAE is proven to be causally related to the vaccine,” the consent form said.

In phase 1 and phase 2 clinical trials, Covaxin has demonstrated the ability to produce antidotes against COVID- 19. However, the clinical efficacy of the vaccine was yet to be established and it was still being studied in phase 3 clinical trials, the vaccine maker said.

“Hence it is important to appreciate that receiving the vaccine does not mean that other precautions related to COVID-19 need not be followed,” the consent form said.

According to an industry expert, the company is liable to pay compensation to people in case of serious side effects as the vaccine is being administered while in the clinical trial mode.

The central licensing authority has granted permission for the sale or distribution of Covaxin for restricted use in emergency situations in public interest as an abundant caution, in clinical trial mode.

Meanwhile, Suchitra Ella, joint managing director, Bharat Biotech International Limited, on her Twitter account said: “Covaxin & Bharat Biotech is truly humbled & honoured to be of service to the nation & the fraternity of all first responders of covid who have served public health.” — PTI

Continue Reading

Cities

AIIMS security guard reports allergy post COVID vaccination, in hospital care

Delhi has reported 52 adverse events following events of which one is serious and could involve the guard hospitalised today.

Published

on

By

Vaccine

New Delhi, January 16

A 22-year-old security guard at AIIMS, New Delhi reported allergic reaction and is learnt to be in intensive care, moments after the government said there was no post-vaccine hospitalisation.

The 22-year-old guard developed headache, rash, respiratory distress, tachycardia after vaccination. He is in ICU and his condition is stable, hospital sources said.

Delhi has reported 52 adverse events following events of which one is serious and could involve the guard hospitalised today.

All beneficiaries vaccinated at AIIMS got indigenous COVAXIN.

Continue Reading
Advertisement

Most Popular